Misonix

StarFish Contribution

Misonix partnered with StarFish Medical to support the development of the Nexus ultrasonic surgical platform. StarFish contributed to system architecture, mechanical integration, and industrial design to help merge ultrasonic and RF technologies in one platform. The team’s efforts supported the creation of easy-to-use surgical system with a touchscreen interface and proprietary control algorithms.

$100M Valuation

In 2021, Misonix was acquired by Bioventus for approximately $518 million, recognizing the company’s innovative ultrasonic surgical and debridement systems. The acquisition expanded Bioventus’ advanced surgical portfolio and position Misonix’s technology as a leader in minimally invasive tissue management.